Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975
Debt
Debt-to-Equity RatioN/A
Current Ratio18.24
Quick Ratio18.24
Price-To-Earnings
Trailing P/E Ratio-1.87
Forward P/E Ratio-4.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales114.73
Cash FlowN/A
Price / CashN/A
Book Value$3.97 per share
Price / Book2.77
Profitability
EPS (Most Recent Fiscal Year)($5.88)
Net Income$-40,370,000.00
Net MarginsN/A
Return on Equity-49.62%
Return on Assets-44.73%
Miscellaneous
Employees63
Outstanding Shares25,450,000
Market Cap$279.95
Synlogic (NASDAQ:SYBX) Frequently Asked Questions
What is Synlogic's stock symbol?
Synlogic trades on the NASDAQ under the ticker symbol "SYBX."
When did Synlogic's stock split? How did Synlogic's stock split work?
Synlogic's stock reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.
How were Synlogic's earnings last quarter?
Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.18. The biotechnology company earned $0.35 million during the quarter, compared to analyst estimates of $0.21 million. View Synlogic's Earnings History.
When is Synlogic's next earnings date?
What price target have analysts set for SYBX?
5 brokers have issued 1 year target prices for Synlogic's shares. Their forecasts range from $15.00 to $25.00. On average, they anticipate Synlogic's stock price to reach $19.60 in the next twelve months. This suggests a possible upside of 78.2% from the stock's current price. View Analyst Ratings for Synlogic.
What is the consensus analysts' recommendation for Synlogic?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Synlogic stock?
Here are some recent quotes from research analysts about Synlogic stock:
- 1. HC Wainwright analysts commented, "We reiterate our Buy rating and $20 12-month target on SYBX." (6/11/2018)
- 2. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (5/22/2018)
Are investors shorting Synlogic?
Synlogic saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 1,558,261 shares, an increase of 120.1% from the June 15th total of 708,076 shares. Based on an average daily volume of 302,181 shares, the days-to-cover ratio is currently 5.2 days. Approximately 9.8% of the company's stock are sold short. View Synlogic's Current Options Chain.
Who are some of Synlogic's key competitors?
Some companies that are related to Synlogic include Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Flexion Therapeutics (FLXN), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Omeros (OMER), TG Therapeutics Inc common stock (TGTX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), AC Immune (ACIU), Epizyme (EPZM), OptiNose (OPTN), Rhythm Pharmaceuticals (RYTM) and Assembly Biosciences (ASMB).
Who are Synlogic's key executives?
Synlogic's management team includes the folowing people:
- Dr. Peter Barrett, Exec. Chairman (Age 65)
- Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Interim Pres, CEO & Chief Medical Officer (Age 43)
- Mr. Paul Francis Miller Ph.D., Chief Scientific Officer (Age 58)
- Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
- Prof. Timothy K. Lu, Co-Founder
Has Synlogic been receiving favorable news coverage?
News headlines about SYBX stock have trended somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synlogic earned a media sentiment score of 0.22 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.22 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Synlogic?
Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synlogic's stock price today?
One share of SYBX stock can currently be purchased for approximately $11.00.
How big of a company is Synlogic?
Synlogic has a market capitalization of $279.95 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.
How can I contact Synlogic?
Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]
MarketBeat Community Rating for Synlogic (NASDAQ SYBX)
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
